Teriparatide Injection (Zhengu) 20??g – Low price wholesale comparison

Teriparatide Injection (Zhengu) 20??g – Low price wholesale comparison

$2.00

Teriparatide Injection (Zhengu) contains recombinant human PTH (1-34) at 20??g/dose in 80??L, provided in a 2.4?mL vial (5 vials per box). Manufactured by Shanghai United Cell Biotechnology Co., Ltd. Approved under NMPA S20240005. Strictly for laboratory research use only.?Please consult staff for other specifications and uses?

EMI starting from $0.00/month - View Plans

Description

Teriparatide is a recombinant peptide, representing the first 34 amino acids of human parathyroid hormone. It has a robust anabolic effect on bone through intermittent PTH receptor activation. Zhengu provides 20??g doses in pre-filled vials, each containing 2.4?mL for precise subcutaneous or intravenous delivery—suitable for investigative studies in bone metabolism, osteogenesis, and biomarker analysis.

Developed by Shanghai United Cell Biotechnology Co., Ltd., recognized for biosimilar PTH products . NMPA approval number S20240005, drug code 86900719000097.

?? For laboratory research use only. Not for clinical, therapeutic, or veterinary application.


Product Specifications

ParameterDetails
Product NameTeriparatide Injection (Zhengu)
Generic NameTeriparatide (rhPTH 1?34)
CAS Number52232?67?4
Molecular FormulaC???H???N??O??S?
Molecular Weight~4,117.8?Da
Dosage FormRecombinant peptide injection
Strength20??g per 80??L dose in 2.4?mL vial
Packaging5 vials per box
Approval NumberS20240005 (China NMPA)
Product Code86900719000097
ManufacturerShanghai United Cell Biotechnology Co., Ltd.
Storage ConditionsStore at 2–8?°C; protect from light and avoid freezing
Intended UseLaboratory research only

Mechanism & Research Applications

Teriparatide mimics intermittent PTH exposure, stimulating osteoblast differentiation and increasing bone formation markers while promoting bone remodeling. It’s utilized in studies such as:

  • In vitro osteoblast and osteocyte assays

  • Bone mineral density and fracture healing models

  • Biomarker quantification (e.g., P1NP, BSAP)

  • Preclinical osteoporosis and skeletal regeneration studies


Teriparatide Side Effects (Research Context)

Preclinical data and clinical analogues indicate potential effects:

  • Transient hypercalcemia and phosphaturia

  • Injection-site discomfort and mild erythema

  • Occasionally, nausea, headache, or dizziness

  • Long-term animal models may show osteosarcoma incidence (not confirmed in humans)


Safety & Handling

  • Usage Restriction: Laboratory research only; not approved for therapeutic or diagnostic use

  • Handling: Use sterile techniques and PPE (gloves, lab coat, goggles) during administration

  • Storage: Maintain 2–8?°C; discard after expiration

  • Disposal: Dispose per institutional biohazard protocols


Core Keywords

Teriparatide injection, Zhengu teriparatide, rhPTH 1-34 injectable, bone formation research, lab-grade osteoporosis peptide, NMPA S20240005 teriparatide, Shanghai United Cell PTH, wholesale teriparatide injection


Research Use Disclaimer

This product is exclusively for laboratory research. It is not approved for clinical, therapeutic, diagnostic, or veterinary use. Misuse may cause health or regulatory issues. Always adhere to institutional biosafety and handling protocols.

Additional information

Weight1 kg
Dimensions26 × 23 × 26 cm

Reviews

There are no reviews yet.

Be the first to review “Teriparatide Injection (Zhengu) 20??g – Low price wholesale comparison”

Your email address will not be published. Required fields are marked *

EMI Options